The Sign-Up Curve Nobody Predicted

Pharmacies saw demand almost immediately. CVS Health said it had filled about 100,000 Bridge prescriptions by mid-August, and Walgreens reported a similar figure, NPR reported. Walmart and Sam’s Club said they were processing Bridge prescriptions at more than 5,000 pharmacies. Walgreens added that about half of its Bridge patients had never taken a GLP-1 before, which suggests the program is reaching new patients rather than only moving existing cash buyers.

Prescription data point the same way. Truveta, a health data company, reported that GLP-1 prescribing among adults 65 and older rose 19% from June to July 2026, the largest single month-over-month increase in more than seven years of its data. Senior prescriptions for Zepbound jumped 80.1% and for Wegovy 40.9% in that period, according to TechTarget’s report on the data.

A Signal, Not Yet a Scorecard

Sign-ups are not the same as people taking the medicine. NPR noted it was unclear whether everyone counted had received an approved prior authorization, and CMS did not give NPR its own uptake figures. Some patients will also stop because of side effects such as nausea and diarrhea, which commonly appear early in treatment. Walgreens’ Rick Gates expects participation to reach a “ceiling point” and settle into a “natural run rate of patients that stay on” therapy. CMS has said it plans to begin sharing monthly utilization reports with Part D plans this fall.

Who Qualifies for the $50 Price

The Bridge is narrower than “anyone on Medicare who wants to lose weight.” According to the Medicare.gov fact sheet, you must have Part D drug coverage, through a stand-alone drug plan or a Medicare Advantage plan with drug coverage, and you cannot already be getting a GLP-1 paid for by your Part D plan. You also must be at least 18 and meet one of three BMI-based tiers, with BMI calculated by your doctor.

The three tiers, as Medicare lists them, are a BMI of 35 or higher on its own; a BMI of 30 or higher plus certain heart failure, hard-to-control high blood pressure or chronic kidney disease stage 3a or above; or a BMI of 27 or higher plus prediabetes, a prior heart attack, a prior stroke or blocked arteries in the legs or arms. KFF estimated that 3.8 million Part D enrollees could qualify, about 8% of all Part D enrollees.

The Exclusion That Surprises People

If you have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease, you are not eligible for the Bridge. That is not because Medicare does not want to help. These conditions already qualify for GLP-1 coverage through regular Part D, where FDA-approved uses such as Ozempic or Mounjaro for diabetes and Zepbound for sleep apnea can be covered under your plan’s rules. Medicare tells these beneficiaries to contact their drug plan instead.

How to Get the Drug, Step by Step

You do not apply through your Part D plan. AARP’s guidance is to skip the plan and start with your doctor, and Medicare’s fact sheet lays out the sequence below. The approval comes from Medicare, and you receive a letter confirming coverage.

1. 1Talk to your doctorAsk whether a covered GLP-1 is right for you and whether your BMI and conditions qualify.
2. 2Get a prescription sentYour doctor sends it to a participating pharmacy for Wegovy, Foundayo or the Zepbound KwikPen.
3. 3Pharmacy checks eligibilityBring your Medicare card; the pharmacist can also look you up with the last four digits of your Social Security number.
4. 4Doctor submits the approval formAfter the pharmacy confirms eligibility, your doctor requests Medicare’s approval.
5. 5Watch for Medicare’s letterYou receive written confirmation of coverage.
6. 6Pay $50 and pick upRefills on the same drug do not need new approval, even if your dose changes.

If Your Request Is Turned Down

The Bridge works outside the usual Part D rules, and a CMS official told AARP, “There won’t be a formal appeals process.” If a request contained inaccurate information or something new comes up, your doctor can update and resubmit it. Coverage decisions made by your regular Part D plan, such as for diabetes or sleep apnea uses, can still be appealed through standard Medicare channels.

The Money: What You Save and What Medicare Spends

The savings for an eligible enrollee are large. Oz said the typical cost had been about $1,200 a month; Klomp used $900 as an example. Even against today’s lower manufacturer self-pay prices of $349 for a Wegovy pen or $449 for higher Zepbound KwikPen doses, $50 is a steep discount.

For Medicare, the math is bigger. With a negotiated price of $245 and a $50 copay, Medicare pays about $195 a month per enrollee, a figure derived from the published price and copay. KFF estimated the 18-month cost at $1.3 billion if 10% of eligible people participate, rising to $10 billion at 75%. For context, NPR noted Part D drug spending was $181 billion in 2025.

The Savings Debate

The administration argues the program can pay for itself. “We project we’ll actually be able to save money for the taxpayer,” Oz said. Eli Lilly research found sustained Zepbound use in older adults with obesity lowered overall costs by up to 15% at six months and up to 38% at 12 months, compared with untreated patients, though that is company-sponsored research. The Congressional Budget Office has been more skeptical, estimating that broad Medicare coverage of weight-management drugs would add $35.5 billion in federal spending from 2026 to 2034, with about $1 billion in health care savings over the same period.

If the 1.1 million sign-ups all filled prescriptions every month, participation would be roughly 29% of KFF’s 3.8 million eligible estimate, a calculation that likely overstates active use. That would put costs between KFF’s 25% and 50% scenarios. USC health economist Jeremy Shane told NPR the early numbers are “encouraging about the demand for those medications,” adding that “cost is the wrong way of looking at it.”

How the Bridge Came Together and Where It Goes Next

The Bridge was originally meant to be just that: a short-term link to a broader model called BALANCE, which would have paired lower drug prices with nutrition and fitness coaching for Medicare and Medicaid enrollees. In April 2026, CMS dropped the Medicare portion of BALANCE after weak interest from Part D insurers, according to TechTarget. CMS has not set a new timeline for it.

1. Nov. 2025White House announces drug pricing deals with Eli Lilly and Novo Nordisk that set the stage for Medicare access.
2. April 2026CMS drops the Medicare part of the BALANCE model after weak insurer interest.
3. July 1, 2026Bridge launches with a $50 copay for eligible Part D enrollees.
4. July 29, 2026Oz reports about 250,000 sign-ups.
5. Mid-Aug. 2026CVS reports about 100,000 Bridge prescriptions filled.
6. Aug. 31, 2026Oz reports about 600,000 seniors enrolled.
7. Oct. 7, 2026Klomp puts sign-ups at about 1.1 million.
8. Fall 2026CMS plans monthly utilization reports to Part D plans.
9. Dec. 31, 2027Bridge is scheduled to end after 18 months.

The 2027 Cliff Question

Gates called the program’s end the “biggest watch-out,” asking what happens to patients still on these drugs after 18 months. CMS plans to review 18 months of data before deciding whether the Bridge continues. That matters because many people regain weight after stopping GLP-1s. If you start now, talk with your doctor about a plan for 2028, whether that means self-pay pricing, a future Medicare program or another approach, and keep an eye on announcements during Medicare open enrollment next fall.

Open Enrollment Has a Bridge Angle

Medicare’s annual open enrollment runs from October 15 to December 7. The Bridge requires Part D coverage, so if you currently have no drug coverage, enrolling in a Part D plan or a Medicare Advantage plan with drug coverage for 2027 is the first step toward eligibility. Late-enrollment penalties can apply if you went without creditable drug coverage, so check your situation with 1-800-MEDICARE or your State Health Insurance Assistance Program.

• Confirm Part D coverageStand-alone or Advantage with drugs
• Check your BMI tier35, or 30 or 27 with conditions
• Rule out excluded diagnosesDiabetes, sleep apnea, fatty liver
• Use a covered formZepbound KwikPen, not vials
• Budget $600 a yearOutside your Part D cap
• Plan for Dec. 31, 2027Ask your doctor about next steps